ASH 2021 | Assessing BGB-11417, a novel BCL2 inhibitor, in NHL
Constantine Tam
• 12 Dec 2021
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, The Peter MacCallum Cancer Centre, Melbourne, Australia, discusses preliminary data from the Phase I BGB-11417-101 trial (NCT04277637) of BGB-11417, a novel BCL2 inhibitor, with zanubrutinib in patients with non-Hodgkin lymphoma (NHL). Patients in the dose-escalation trial reported encouraging efficacies across different indications including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), and the drug additionally demonstrated an acceptable safety profile. BGB-11417 continues to be a promising candidate drug superior to venetoclax. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
